Metastatic Renal Cell Carcinoma Recruiting Phase 2 Trials for Cabozantinib (DB08875)

Also known as: Metastatic Renal cell carcinoma

IndicationStatusPhase
DBCOND0030098 (Metastatic Renal Cell Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03463681A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinomaTreatment
NCT03541902Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell CarcinomaTreatment
NCT03967522Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain MetastasesTreatment